CSIMarket
 


Immucell Corp  (ICCC)
Other Ticker:  
 
 

ICCC's EPS from Cont. Operations Growth by Quarter and Year

Immucell's EPS from Cont. Operations results by quarter and year




ICCC EPS from Cont. Operations (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.22 0.01 0.03
III Quarter September -0.12 -0.08 0.02 -0.04
II Quarter June -0.18 -0.09 0.02 -0.11
I Quarter March -0.30 0.07 -0.06 -0.02
FY   -0.60 -0.32 -0.01 -0.14



ICCC EPS from Cont. Operations third quarter 2023 Y/Y Growth Comment
Immucell Corp in the third quarter 2023 recorded EPS loss from Cont. Operations of $ -0.12 .

According to the results reported in the third quarter 2023, Immucell Corp achieved the best EPS from Cont. Operations growth in In Vitro & In Vivo Diagnostic Substances industry. While Immucell Corp' s EPS from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2023.




ICCC EPS from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - -66.67 % -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Immucell's third quarter 2023 EPS from Cont. Operations $ -0.12 ICCC's Income Statement
Immucell's third quarter 2022 EPS from Cont. Operations $ -0.08 Quarterly ICCC's Income Statement
New: More ICCC's historic EPS from Cont. Operations Growth >>


ICCC EPS from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - -50 % -
III Quarter September - - 0 % -
II Quarter June - - - -
I Quarter March - 600 % - -
FY (Year on Year)   - - - -




EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Immucell's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICCC's III. Quarter Q/Q EPS from Cont. Operations Comment
Even if Immucell Corp in the III. Quarter 2023 revealed EPS loss from Cont. Operations of $ -0.12 , it should be said, that current results point to recovery relative to the -0.18 in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Immucell Corp achieved highest sequential EPS from Cont. Operations growth. While Immucell's EPS from Cont. Operations growth quarter on quarter, overall rank is .


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICCC's III. Quarter Q/Q EPS from Cont. Operations Comment
Despite the fact, that Immucell Corp in the III. Quarter 2023 revealed EPS loss from Cont. Operations of $ -0.12 , it should be point out, that current results show improvement relative to the -0.18 in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Immucell Corp achieved highest sequential EPS from Cont. Operations growth. While Immucell's EPS from Cont. Operations growth quarter on quarter, overall rank is .


Immucell's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative EPS from Cont. Operations 12 Months Ending $ -0.82 $ -0.78 $ -0.69 $ -0.32 $ -0.09
Y / Y EPS from Cont. Operations Growth (TTM) - - - - -
Year on Year EPS from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential EPS from Cont. Operations Change (TTM) - - - - -
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative EPS from Cont. Operations growth Comment
Immucell Corp' has realized cumulative trailing twelve months EPS loss from Cont. Operations of $ -1 in the Sep 30 2023 period.
The situation is worsening as the cumulative EPS loss from Cont. Operations is inflating from $ -0.78 in the twelve months ending a quarter before and $ 0.0095666056887068 for the twelve months ending in the quarter Sep 30 2022.

Immucell Corp achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS from Cont. Operations growth Comment
Immucell Corp' has realized cumulative trailing twelve months EPS loss from Cont. Operations of $ -1 in the Sep 30 2023 period.
The results are getting worse as the cumulative EPS loss from Cont. Operations is becoming larger from $ -0.78 for the period from Jun 30 2023 to Sep 30 2022 and $ 0.0095666056887068 from the TTM period ending Sep 30 2022.

Immucell Corp achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS from Cont. Operations Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
ICCC's EPS from Cont. Operations Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for ICCC's Competitors
EPS from Cont. Operations Growth for Immucell's Suppliers
EPS from Cont. Operations Growth for ICCC's Customers

You may also want to know
ICCC's Annual Growth Rates ICCC's Profitability Ratios ICCC's Asset Turnover Ratio ICCC's Dividend Growth
ICCC's Roe ICCC's Valuation Ratios ICCC's Financial Strength Ratios ICCC's Dividend Payout Ratio
ICCC's Roa ICCC's Inventory Turnover Ratio ICCC's Growth Rates ICCC's Dividend Comparisons



Companies with similar EPS from Cont. Operations no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Sep 30 2023
Molecular Templates inc 86.36%$ 86.364 
Select Medical Holdings Corp80.95%$ 80.952 
Align Technology inc 70.97%$ 70.968 
Integer Holdings Corporation70.83%$ 70.833 
Docgo Inc 66.67%$ 66.667 
Merit Medical Systems Inc66.67%$ 66.667 
Infusystem Holdings Inc50.00%$ 50.000 
Semler Scientific Inc 49.09%$ 49.091 
Incyte Corporation49.02%$ 49.020 
Iradimed Corporation48.15%$ 48.148 
Option Care Health Inc 47.62%$ 47.619 
Merck and Co Inc 46.09%$ 46.094 
Msa Safety Incorporated44.35%$ 44.348 
Teva Pharmaceutical Industries Limited40.00%$ 40.000 
Halozyme Therapeutics Inc 37.78%$ 37.778 
Lemaitre Vascular Inc 36.00%$ 36.000 
Encompass Health Corporation34.38%$ 34.375 
West Pharmaceutical Services Inc 33.95%$ 33.951 
Lftd Partners Inc 33.33%$ 33.333 
Addus Homecare Corporation31.51%$ 31.507 
Chemed Corporation30.10%$ 30.105 
Intuitive Surgical Inc 29.67%$ 29.670 
Bristol myers Squibb Company25.33%$ 25.333 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com